Where to buy Defibrotide?

Defibrotide is a polydeoxyribonucleic acid salt that has certain fibrinolytic and antithrombotic activities and can promote the production of prostacyclin-like substances and release them from vascular tissues into the circulation. This medicine is indicated for the treatment of adult and pediatric patients with hepatic venous occlusion (VOD) and associated renal or pulmonary abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT).

Hepatic venule occlusion causes edema and reduced blood flow in the liver due to blockage of some blood vessels in the liver. This condition can lead to the most severe liver damage. The drug is the first drug approved by the FDA for the treatment of severe hepatic venous occlusion, a rare and fatal liver disease.

The approval was based on a Phase 2 trial of 75 patients, a Phase 3 trial of 102 patients, and an expansion trial of an additional 351 patients. All patients in the trial were diagnosed with hepatic VOD and associated renal or pulmonary dysfunction after HSCT. In the phase 2 trial, 44% of patients survived 100 days after transplantation, compared with 38% in the phase 3 trial and 45% in the expanded trial, and the FDA noted in a report that the expected 100-day survival rate for patients with severe hepatic VOD who were not treated with Defibrotide was 21%-31%.

Data on the drug's safety are based on 176 patients. The most common adverse reactions include hypotension, diarrhea, vomiting, nausea, and epistaxis. The most common serious adverse reactions include hypotension and alveolar hemorrhage. The approval of Defibrotide greatly meets the treatment needs of transplant patients suffering from such rare and fatal complications.

If patients want to buy Defibrotide, they can first go to a foreign pharmacy to buy it in person, or they can choose a domestic regular medical service institution, such as Medical Companion Travel, which can help patients have the medicine delivered directly to their home without having to worry about the source of the medicine. It is not recommended that patients choose purchasing agents. This method is relatively risky and may result in ineffective medicines, delaying subsequent treatment.